Ken Griffin Lantern Pharma Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,400 shares of LTRN stock, worth $63,848. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,400
Previous 16,400
12.2%
Holding current value
$63,848
Previous $51,000
56.86%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LTRN
# of Institutions
33Shares Held
2.26MCall Options Held
18.4KPut Options Held
0-
Bios Capital Management, LP Fort Worth, TX1.02MShares$3.52 Million4.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA384KShares$1.33 Million0.0% of portfolio
-
Cm Management, LLC225KShares$780,7500.92% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny100KShares$347,3470.0% of portfolio
-
Geode Capital Management, LLC Boston, MA92.1KShares$319,5210.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $37.6M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...